Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. MarketScreener Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca : QUOTES-EU regulator finds link between AstraZeneca vaccine and blood clots

04/07/2021 | 11:39am EDT

April 7 (Reuters) - Europe's drug regulator on Wednesday found a possible link between AstraZeneca's COVID-19 vaccine and rare blood clots in adults who had received the inoculation.

The announcement is a fresh setback for the vaccine, which is sold at cost, for a few dollars a dose, and is by far the cheapest and most high-volume launched so far.

The following are reactions to the latest developments.

EMER COOKE, EXECUTIVE DIRECTOR OF EUROPEAN MEDICINES AGENCY (EMA)

"The risk of mortality from COVID is much greater than the risk of mortality from these rare side effects."

DR. SABINE STRAUS, CHAIR OF EMA'S SAFETY COMMITTEE (PRAC)

"This is not unexpected. We know that we are rolling out vaccines on a very large scale ... we will see events occurring ... some of them by chance."

DR. JACQUES BATTISTONI, HEAD OF FRENCH DOCTORS' UNION MG

"This time, the EMA confirms clearly that there is a link between vaccination and serious adverse effects. But these events are exceptional.

"Other medications also pose such risks.

"Will vaccination with AstraZeneca be harder? Most certainly. We will need to explain further and convince our patients that the benefits outweigh the risks, and that 'zero risk' just does not exist.

"We have a lot work ahead of us. However, we cannot give up on the AstraZeneca, we do not have enough doses to allow that."

WEI SHEN LIM, CHAIR OF BRITAIN'S JOINT COMMITTEE ON VACCINATION AND IMMUNISATION (JCVI)

"We are not advising a stop to any vaccination for any individual in any age group. We are advising a preference for one vaccine over another vaccine for a particular age group, really out of the utmost caution, rather than because we have any serious safety concerns."

"Those who have received their first dose of AstraZeneca vaccine should continue to be offered the second dose of AstraZeneca vaccine, according to the set schedule."

PROFESSOR ANTHONY HARNDEN, DEPUTY CHAIR OF JCVI

"What is clear is that for the vast majority of people the benefits of the Oxford AZ (AstraZeneca) vaccine far outweigh any extremely small risk and the Oxford AZ vaccine will continue to save many from suffering the devastating effects that can result from a COVID infection."

DAVID WERRING, PROFESSOR OF CLINICAL NEUROLOGY, UCL INSTITUTE OF NEUROLOGY

"We still urgently need more research to first understand which individuals are at highest risk of these unusual blood clots in the brain, which although very rare, can often be serious or fatal."

DR. MICHAEL HEAD, SENIOR RESEARCH FELLOW IN GLOBAL HEALTH, UNIVERSITY OF SOUTHAMPTON

"The Oxford AstraZeneca vaccine is a vital tool in the global strategy to contain the pandemic. It is being manufactured in large numbers, is stored at refrigeration temperatures and thus easier to transport, cost per dose is cheap, and key to the COVAX distribution to low- and lower-middle income countries.

"Maintaining public confidence is so important. An open, transparent process to assessing safety concerns must be part of that."

DR. WILLIAM SCHAFFNER, AN INFECTIOUS DISEASE EXPERT AT VANDERBILT UNIVERSITY MEDICAL CENTER IN NASHVILLE

"This is a classically difficult risk-benefit analysis. We know that no vaccine is totally free of adverse events, even the occasional serious adverse event, and this is a serious event."

"We're in this very difficult circumstance because this vaccine should be the cheapest and can be handled easily in normal refrigerator temperatures. It was probably going to be the dominant vaccine internationally, and that makes all of this much more poignant."

DR. AMESH ADALJA, AN INFECTIOUS DISEASE EXPERT AT THE JOHNS HOPKINS CENTER FOR HEALTH SECURITY IN BALTIMORE

"Even if the blood clots could be causally linked to the AstraZeneca vaccine, the risk-benefit ratio still favors the vaccine."

"I think that every negative headline about the AstraZeneca vaccine is going to add to vaccine hesitancy because, in general, the public doesn't remember any of the details or how low the risk is. What they remember is the headline."

(Compiled by Reuters staff Editing by Kevin Liffey, Matthew Lewis and Alison Williams)


© Reuters 2021
All news about ASTRAZENECA PLC
04/16ASTRAZENECA  : Quebec to deploy sound trucks in Montreal to announce mobile vacc..
AQ
04/16ASTRAZENECA  : Doctors say lowering age cutoff for AstraZeneca vaccine makes sen..
AQ
04/16Consumer Cos Climb On Reopening Optimism -- Consumer Roundup
DJ
04/16Health Care Up After Strong Start to Earnings Season -- Health Care Roundup
DJ
04/16Vaccine Manufacturing Issues Force Moderna to Cut Supplies to Canada, U.K.
DJ
04/16No Causal Link Found So Far Between J&J's Covid-19 Vaccine and Blood-Clot Cas..
DJ
04/16ASTRAZENECA  : German's IDT to make 10M AstraZeneca vaccine doses in 2021
AQ
04/16ASTRAZENECA  : Covid-19 - Lagos, Kano Lead As Nigeria Vaccinates Over 1m Persons
AQ
04/16MARKET CHATTER : Johnson & Johnson Reportedly Asked Other COVID-19 Vaccine Produ..
MT
04/16ASTRAZENECA  : Australia's Medicine Watchdog Links Woman's Death To AstraZeneca ..
MT
More news
Financials (USD)
Sales 2021 30 805 M - -
Net income 2021 5 064 M - -
Net Debt 2021 11 692 M - -
P/E ratio 2021 26,1x
Yield 2021 2,79%
Capitalization 134 B 134 B -
EV / Sales 2021 4,73x
EV / Sales 2022 4,09x
Nbr of Employees 76 100
Free-Float 95,8%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 25
Average target price 129,60 $
Last Close Price 102,07 $
Spread / Highest target 62,6%
Spread / Average Target 27,0%
Spread / Lowest Target -7,74%
EPS Revisions
Managers and Directors
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA PLC0.76%133 897
JOHNSON & JOHNSON3.09%422 260
ROCHE HOLDING AG0.16%289 178
PFIZER INC.2.15%209 739
NOVARTIS AG-3.73%197 072
MERCK & CO., INC.-5.29%194 049